Overexpression and Purification of Human Cis-prenyltransferase in Escherichia coli
August 3rd, 2017
6.4K views
A simple protocol for overexpression and purification of codon-optimized, human cis-prenyltransferase, under non-denaturing conditions, from Escherichia coli, is described, along with an enzymatic activity assay. This protocol can be generalized for production of other cis- prenyltransferase proteins in quantity and quality suitable for mechanistic studies.
Overview
This protocol outlines the overexpression and purification of codon-optimized human cis-prenyltransferase under non-denaturing conditions, along with an enzymatic activity assay. It aims to enhance understanding of isoprenoid synthesis and its implications in retinitis pigmentosa.
Key Study Components
Area of Science
- Biochemistry
- Enzymology
- Molecular Biology
Background
- Cis-prenyltransferases are crucial for isoprenoid biosynthesis.
- Mutations in DHDDS are linked to retinitis pigmentosa.
- Understanding these enzymes can provide insights into metabolic pathways.
- Current methods for protein production can be inefficient.
Purpose of Study
- To develop a simple and effective protocol for protein overexpression.
- To purify human DHDDS for further mechanistic studies.
- To assess enzymatic activity of the purified protein.
Methods Used
- Cloning of human DHDDS gene.
- Expression in Escherichia coli.
- Purification under non-denaturing conditions.
- Enzymatic activity assay to evaluate functionality.
Main Results
- Successful overexpression of human cis-prenyltransferase.
- High-quality purification achieved under non-denaturing conditions.
- Demonstrated enzymatic activity of the purified protein.
- Protocol can be adapted for other cis-prenyltransferases.
Conclusions
- This method is simple, cost-effective, and time-saving.
- It facilitates the study of isoprenoid synthesis mechanisms.
- Potential to advance research on retinitis pigmentosa.
Frequently Asked Questions
What is the significance of DHDDS?
DHDDS is involved in isoprenoid biosynthesis and is linked to retinitis pigmentosa.
How does this protocol improve protein production?
It offers a simple and efficient method for overexpressing and purifying proteins.
Can this method be applied to other proteins?
Yes, it can be generalized for other cis-prenyltransferase proteins.
What are the advantages of non-denaturing purification?
It preserves protein functionality and structure, allowing for accurate activity assays.
Is this protocol cost-effective?
Yes, it is designed to be simple and reduce costs associated with protein production.
What type of assays can be performed with the purified protein?
Enzymatic activity assays can be performed to evaluate the functionality of the protein.
Executive Industry Relevance
This protocol enables high-yield production of functional human DHDDS, a key enzyme in isoprenoid biosynthesis whose mutations cause retinitis pigmentosa. By providing a reliable source of purified protein, it supports target validation and mechanistic de-risking in early discovery programs focused on retinal degeneration pathways. The approach offers a scalable, cost-effective solution for generating biochemical tools to interrogate therapeutic hypotheses and prioritize preclinical candidates.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Scientific Value: Enables interrogation of DHDDS function and pathogenic mechanisms linked to retinal degeneration.
- Operational Value: Provides purified protein for biochemical assays that clarify target biology and support hypothesis-driven screening.
Screening & Assay Development
- Scientific Value: Generates enzymatically active DHDDS suitable for developing quantitative assays measuring isoprenoid synthase activity.
- Operational Value: Delivers reproducible protein batches enabling assay standardization and hit validation in compound screening campaigns.
Translational & Preclinical Research
- Scientific Value: Supports mechanistic studies connecting DHDDS dysfunction to disease phenotypes, aiding translational biomarker exploration.
- Operational Value: Facilitates preclinical evaluation of modulation strategies by supplying consistent, active enzyme for pathway analysis.
Pipeline & Workflow Integration
The method fits within early discovery workflows, supplying purified target for assay development and lead identification efforts focused on isoprenoid pathway modulation.
- Discovery Biology: Enables functional validation of DHDDS as a therapeutic target through activity-based assays and mechanistic probing.
- Screening: Produces standardized enzyme for high-confidence screening of compounds affecting prenyltransferase activity.
- Analytics: Generates quantitative time-dependent activity data (e.g., C14 IPP incorporation) to assess compound effects and target engagement.
- Translational Research: Supports continuity from target validation to preclinical models by providing tools to study disease-relevant enzymatic dysfunction.
- Enterprise Reuse: Establishes a reusable platform for producing other eukaryotic cis-prenyltransferases, enhancing cross-project efficiency.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence in target validation by enabling direct measurement of enzymatic function and mutation impact.
- Operational Value: Ensures reproducibility and scalability of protein production, reducing variability in downstream assays.
- Strategic Value: Improves go/no-go decisions by de-risking target biology early, minimizing investment in poorly validated targets.
- Portfolio Impact: Enables data-driven prioritization of targets in isoprenoid-related pathways through reliable biochemical readouts.
Implementation Considerations
- Requires expertise in molecular cloning, protein expression, and chromatographic purification techniques.
- Depends on access to FPLC systems, centrifugation equipment, and scintillation counters for activity assays.
- Necessitates standardization of buffer conditions and imidazole gradients across purification steps to ensure consistency.
- Involves optimization of induction parameters and host strains for soluble expression in E. coli.
- Activity assays require handling of radiolabeled substrates and organic extraction steps, necessitating appropriate safety controls.
Biopharma FAQs
Why does measuring C14 IPP incorporation matter for target validation?
Quantifying C14 IPP incorporation over time provides a direct readout of DHDDS enzymatic activity, enabling assessment of wild-type versus mutant enzyme function. This measurement supports target validation by linking biochemical activity to pathophysiological mechanisms in retinitis pigmentosa.
How does isolating the soluble fraction enable discovery pipeline progression?
Isolating the soluble fraction after cell lysis enriches for properly folded, functional DHDDS, which is essential for downstream activity assays and target validation. This step ensures that subsequent purification yields enzymatically active protein suitable for screening and mechanistic studies.
What do quantitative dependent variable measurements enable in assay development?
Quantitative measurements of reaction products, such as extracted prenyl chains in the butanol phase, allow precise determination of enzyme kinetics and inhibition profiles. These data support assay standardization and hit confirmation in screening campaigns targeting isoprenoid biosynthesis.
Why do replication requirements matter for cross-functional collaboration?
Replicating purification and activity assays across experiments ensures consistent protein quality and reliable data, which is critical for aligning discovery, screening, and preclinical teams. Consistent outputs enable confident comparison of results and informed decision-making across functions.
What statistical analysis capabilities are required before implementation?
The ability to calculate net C14 IPP incorporation as a percentage of total radioactivity and plot results over time is required to assess enzymatic activity trends. This analysis enables objective comparison of reaction progress and supports go/no-go decisions based on functional protein yield.
